Will Hsp90 Inhibitors Prove Effective in BRAF-Mutant Melanomas?CATALANOTTI, Federica; SOLIT, David B.Clinical cancer research (Print). 2012, Vol 18, Num 9, pp 2420-2422, issn 1078-0432, 3 p.Article

Development and application of Hsp90 inhibitorsSOLIT, David B; CHIOSIS, Gabriela.Drug discovery today. 2008, Vol 13, Num 1-2, pp 38-43, issn 1359-6446, 6 p.Article

KRAS and BRAF: drug targets and predictive biomarkersVAKIANI, Efsevia; SOLIT, David B.Journal of pathology (Print). 2011, Vol 223, Num 2, pp 219-229, issn 0022-3417, 11 p.Article

Induction of Cutaneous Squamous Cell Carcinomas by RAF Inhibitors: Cause for Concern?LACOUTURE, Mario E; O'REILLY, Kathryn; ROSEN, Neal et al.Journal of clinical oncology. 2012, Vol 30, Num 3, pp 329-330, issn 0732-183X, 2 p.Article

Hsp90 as a therapeutic target in prostate cancerSOLIT, David B; SCHER, Howard I; ROSEN, Neal et al.Seminars in oncology. 2003, Vol 30, Num 5, pp 709-716, issn 0093-7754, 8 p.Article

Oncogenic Activation of Pak1-Dependent Pathway of Macropinocytosis Determines BCG Entry into Bladder Cancer CellsREDELMAN-SIDI, Gil; LYER, Gopa; SOLIT, David B et al.Cancer research (Chicago, Ill.). 2013, Vol 73, Num 3, pp 1156-1167, issn 0008-5472, 12 p.Article

Targeting Oncogenic BRAF in Human CancerPRATILAS, Christine A; FENG XING; SOLIT, David B et al.Current Topics in Microbiology and Immunology. 2012, Vol 355, pp 83-98, issn 0070-217X, 16 p.Article

Inhibition of heat shock protein 90 function down-regulates Akt kinase and sensitizes tumors to taxolSOLIT, David B; BASSO, Andrea D; OLSHEN, Adam B et al.Cancer research (Baltimore). 2003, Vol 63, Num 9, pp 2139-2144, issn 0008-5472, 6 p.Article

Presence of Somatic Mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in Cisplatin-Resistant Germ Cell TumorsFELDMAN, Darren R; IYER, Gopa; VAN ALSTINE, Lindsay et al.Clinical cancer research (Print). 2014, Vol 20, Num 14, pp 3712-3720, issn 1078-0432, 9 p.Article

Phase II Trial of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with BRAF^V600E/K-Mutated MelanomaCATALANOTTI, Federica; SOLIT, David B; SCHWARTZ, Gary K et al.Clinical cancer research (Print). 2013, Vol 19, Num 8, pp 2257-2264, issn 1078-0432, 8 p.Article

Antitumor Activity of SNX-2112, a Synthetic Heat Shock Protein-90 Inhibitor, in MET-Amplified Tumor Cells with or without Resistance to Selective MET InhibitionBACHLEITNER-HOFMANN, Thomas; SUN, Mark Y; SOLIT, David B et al.Clinical cancer research (Print). 2011, Vol 17, Num 1, pp 122-133, issn 1078-0432, 12 p.Article

Somatic mutation of fibroblast growth factor receptor-3 (FGFR3) defines a distinct morphological subtype of high―grade urothelial carcinomaAL-AHMADIE, Hikmat A; LYER, Gopa; RICHES, Jamie et al.Journal of pathology (Print). 2011, Vol 224, Num 2, pp 270-279, issn 0022-3417, 10 p.Article

The Current State of Preclinical Prostate Cancer Animal ModelsPIENTA, Kenneth J; ABATE-SHEN, Cory; SIMONS, Jonathon W et al.The Prostate. 2008, Vol 68, Num 6, pp 629-639, issn 0270-4137, 11 p.Article

Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptorsSEUNGCHAN YANG; SHIMIAN QU; PEREZ-TORES, Marianela et al.Cancer research (Baltimore). 2006, Vol 66, Num 14, pp 6990-6997, issn 0008-5472, 8 p.Article

SNX2112, a Synthetic Heat Shock Protein 90 Inhibitor, Has Potent Antitumor Activity against HER Kinase : Dependent CancersCHANDARLAPATY, Sarat; SAWAI, Ayana; NORTON, Larry et al.Clinical cancer research. 2008, Vol 14, Num 1, pp 240-248, issn 1078-0432, 9 p.Article

3'-Deoxy-3'-[¹⁸F]Fluorothymidine Positron Emission Tomography Is a Sensitive Method for Imaging the Response of BRAF-Dependent Tumors to MEK InhibitionSOLIT, David B; SANTOS, Elmer; PRATILAS, Christine A et al.Cancer research (Baltimore). 2007, Vol 67, Num 23, pp 11463-11469, issn 0008-5472, 7 p.Article

BRAF mutation predicts sensitivity to MEK inhibitionSOLIT, David B; GARRAWAY, Levi A; GOLUB, Todd R et al.Nature (London). 2006, Vol 439, Num 7074, pp 358-362, issn 0028-0836, 5 p.Article

17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenograftsSOLIT, David B; ZHENG, Fuzhong F; SCHER, Howard I et al.Clinical cancer research. 2002, Vol 8, Num 5, pp 986-993, issn 1078-0432Article

BRAF Mutation Predicts for Poor Outcomes After Metastasectomy in Patients With Metastatic Colorectal CancerYAEGER, Rona; CERCEK, Andrea; SOLIT, David B et al.Cancer. 2014, Vol 120, Num 15, pp 2316-2324, issn 0008-543X, 9 p.Article

Phase II study of everolimus in metastatic urothelial cancerMILOWSKY, Matthew I; IYER, Gopa; BALAR, Arjun V et al.BJU international (Papier). 2013, Vol 112, Num 4, pp 462-470, issn 1464-4096, 9 p.Article

Genomic sequencing of colorectal adenocarcinomas identifies a recurrent YTI1A-TCF7L2 fusionBASS, Adam J; LAWRENCE, Michael S; RUI JING et al.Nature genetics. 2011, Vol 43, Num 10, pp 964-968, issn 1061-4036, 5 p.Article

RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)POULIKAKOS, Poulikos I; PERSAUD, Yogindra; SALTON, Maayan et al.Nature (London). 2011, Vol 480, Num 7377, pp 387-390, issn 0028-0836, 4 p.Article

Randomized, Phase II Study of the Insulin-Like Growth Factor-1 Receptor Inhibitor IMC-A12, With or Without Cetuximab, in Patients With Cetuximab- or Panitumumab-Refractory Metastatic Colorectal CancerREIDY, Diane Lauren; VAKIANI, Efsevia; DONTABHAKTUNI, Aruna et al.Journal of clinical oncology. 2010, Vol 28, Num 27, pp 4240-4246, issn 0732-183X, 7 p.Article

Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignanciesVEERIAH, Selvaraju; TAYLOR, Barry S; LADANYI, Marc et al.Nature genetics. 2010, Vol 42, Num 1, pp 77-82, issn 1061-4036, 6 p.Article

Transcriptional Pathway Signatures Predict MEK Addiction and Response to Selumetinib (AZD6244)DRY, Jonathan R; PAVEY, Sandra; GRAHAM, Alexander et al.Cancer research (Chicago, Ill.). 2010, Vol 70, Num 6, pp 2264-2273, issn 0008-5472, 10 p.Article